Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ketamine for pain control in acute coronary syndrome
IRCT20190611043864N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ketamine in acute coronary syndrome (ACS) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Pain relief. Started Sep 2020; status: completed.
02
Drugs
ketamine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20190611043864N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190611043864N1.